Event tomorrow: Leaders convene to discuss solutions to advance value-driven health care
By Katie Koziara | October 2, 2018
Tomorrow, October 3, PhRMA will convene health care leaders for a discussion on how we can move our health care system toward one focused on value rather than volume, ensuring patients can access...
Read More
New whitepaper identifies reasons why ICER’s cost-effectiveness analyses are not useful for payers
By Lauren Neves | September 19, 2018
A new whitepaper authored by Bruce Pyenson, F.S.A., M.A.A.A. and colleagues from Milliman explains why Institute for Clinical and Economic Review (ICER) cost-effective analyses (CEAs) will not be...
Read More
Guest post: Developing new payment models to ensure patients have access to high-investment therapies
By Guest Contributor | September 6, 2018
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
Number of value-based contracts continues to rise
By Michelle Drozd | August 27, 2018
The list of publicly announced value-based contracts (VBCs) – also called results-based contracts – between biopharmaceutical companies and health plans continued to grow over the last quarter –...
Read More
ICER’s budget impact threshold: Sounding a false alarm on affordability and access
By Randy Burkholder | July 24, 2018
If a home inspector found “wide and unpredictable variation” in your smoke detectors, would you want to fix them?
Read More
PhRMA submission to HHS on blueprint to lower drug prices and reduce out-of-pocket costs
By Holly Campbell | July 16, 2018
Today, PhRMA submitted comprehensive comments to the Department of Health and Human Services (HHS) request for information (RFI), HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs....
Read More
How ICER’s assessment of a new class of migraine treatments fails patients
By Lauren Neves | July 10, 2018
Over 50 million Americans suffer from migraine and the majority of patients affected by this often debilitating disease are between 25 and 55 years old – the time they are most productive in their...
Read More
Aspen Spotlight Health: Discussing the forefront of innovation
By Katie Koziara | June 21, 2018
For the second year in a row, PhRMA is proud to participate in Aspen’s Spotlight Health Conference. As the opening session of Aspen Ideas Festival, Spotlight Health welcomes over 1,500 experts and...
Read More
New analysis shows that HTA organizations may frequently restrict access to cancer treatments
By Randy Burkholder | June 1, 2018
In health care, who should decide value? In many industrialized countries with single-payer health systems, the answer is “the government.” A new analysis by Avalere illustrates the negative...
Read More
New analysis shows negative impact of ICER’s value framework on patient access in Medicare Part B
By Lauren Neves | May 31, 2018
Amidst debate about rising health care costs, some policy-makers have expressed renewed interest in using cost-effectiveness thresholds as the basis for setting coverage and payment policy. But a ...
Read More
Medicare Monday (100)
340B Spotlight (37)
Cost & Consequence (0)
